Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized multicenter study of carboplatin-gemcitabine versus carboplatin-paclitaxel in elderly patients with non-small cell lung cancer with emphasis on geriatric assessment and quality of life: The NVALT-3 study

Next Previous
Trial Profile

A randomized multicenter study of carboplatin-gemcitabine versus carboplatin-paclitaxel in elderly patients with non-small cell lung cancer with emphasis on geriatric assessment and quality of life: The NVALT-3 study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Carboplatin
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms NVALT-3

Most Recent Events

  • 06 Aug 2009 Final results presented as an abstract in association with the 45th Annual Meeting of the American Society of Clinical Oncology, 29 May 2009.
  • 01 May 2009 Status changed from active, no longer recruiting to completed, based on publication and presentation of final results in association with ASCO 2009.
  • 20 Mar 2007 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top